Immunofoco announced that data from its Phase I/IIa clinical trial of IMC002, a VHH-based anti-CLDN18.2 CAR-T cell therapy, will be presented at the 2026 ASCO Gastrointestinal Cancers Symposium (ASCO GI), taking place January 8–10, 2026, in San Francisco, California.

The study evaluates the safety and preliminary efficacy of IMC002 in patients with heavily pretreated, CLDN18.2-positive advanced gastroesophageal cancers. IMC002 is a novel CAR-T therapy constructed using a VHH (nanobody) targeting CLDN18.2, designed to improve tolerability and reduce T-cell exhaustion in solid tumor settings.

Results from the Phase I/IIa trial demonstrate that IMC002 exhibited a favorable safety profile and encouraging, durable antitumor activity in heavily pretreated CLDN18.2-positive advanced GC/GEJ patients. Notably, IMC002 demonstrated significant PFS benefits in 3L+ GC/GEJ patients, with the mPFS data higher than that of GC/GEJ patients at second-line setting, and together with its well-tolerated safety characteristics, supporting its potential to be evaluated in earlier-line treatment strategy.

The data will be presented in a poster session focused on cancers of the esophagus, stomach, and other gastrointestinal malignancies. Immunofoco welcomes clinicians, researchers, and industry colleagues to visit the poster and engage in scientific discussion during the session.

Presentation Details:

· Title: Phase I/IIa trial of efficacy and safety of IMC002, a VHH-based anti-CLDN18.2 CAR-T therapy, for gastroesophageal cancers

· Abstract No.: 398

· Poster Board: E5

· Session: Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers

· Presentation Time: January 8, 2026 | 11:30 AM–1:00 PM; 6:00 PM–7:00 PM (PST)

· Venue: Moscone West Building, San Francisco, USA